The Maxpar Direct Immune Profiling System could lower the threshold to doing mass cytometry due to ease of use, a core lab director said.
Natera and Veracyte both received positive news regarding local coverage determinations from Medicare contractors, while the catalysts for Fluidigm's rise were unclear.
Speakers at this year's ABRF meeting described how they used single-cell tools in combination with other single-cell approaches and other methods.
UBS granted Agilent a Buy rating and a $92 price target; Fluidigm a Neutral rating and a $14 price target; and Qiagen a Neutral rating with a $42 price target.
The index — which outperformed the Dow Jones, the Nasdaq, and the Biotechnology Index this month — gained more than 8 percent.
Revenues from mass cytometry instruments, consumables, and service increased 48 percent to $19.1 million from $12.9 million in Q4 2017.
The firms will cooperatively promote Indica's HALO image analysis tools with Fluidigm's Hyperion imaging mass cytometry platform and related products.
CEO Brad Gray told investors at the JP Morgan Healthcare Conference that he believes the firm's GeoMx has advantages over competitors in the new market.
The Oregon state Senate unanimously passed a bill that would make it easier for people convicted of crimes to initiate DNA testing of evidence, according to the Associated Press.
People reports that researchers have uncovered genetic variants that lead people to always feel full.
Florida state senators are to weigh a bill prohibiting life insurance companies from using genetic information in coverage decisions, according to Florida Politics.
In Genome Research this week: metagenomic sequencing assay that detects pathogens in cerebrospinal fluid, single-tube long fragment read approach, and more.